Terms: = Breast cancer AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA AND Treatment
12 results:
1. The role of the BTLA-hvem complex in the pathogenesis of breast cancer.
Hu X
Breast Cancer; 2024 May; 31(3):358-370. PubMed ID: 38483699
[TBL] [Abstract] [Full Text] [Related]
2. Identification of prognostic biomarkers of breast cancer based on the immune-related gene module.
Wang R; Zeng H; Xiao X; Zheng J; Ke N; Xie W; Lin Q; Zhang H
Autoimmunity; 2023 Dec; 56(1):2244695. PubMed ID: 37584152
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer.
Chen Y; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Wu W; Li X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12145-12164. PubMed ID: 37428249
[TBL] [Abstract] [Full Text] [Related]
4. Design of Sonosensitizers Integrated with Resveratrol Motif for Synergetic Sonodynamic Therapy and Nuclear Factor Kappa B Transcription Suppression of breast cancer.
Li Y; Sun M; Yu J; Jiang W; Tian W; Chen X; Zhang S; He H
J Med Chem; 2023 May; 66(9):6149-6159. PubMed ID: 37075092
[TBL] [Abstract] [Full Text] [Related]
5. Systemic Immune Dysregulation in Early breast cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
Rapoport BL; Steel HC; Hlatshwayo N; Theron AJ; Meyer PWA; Nayler S; Benn CA; Smit T; Kwofie LLI; Heyman L; Anderson R
Front Immunol; 2022; 13():823842. PubMed ID: 35677046
[TBL] [Abstract] [Full Text] [Related]
6. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract] [Full Text] [Related]
7. Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of breast cancer Cells.
Hall BL; Leronni D; Miyagawa Y; Goins WF; Glorioso JC; Cohen JB
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233403
[TBL] [Abstract] [Full Text] [Related]
8. 3.0 T relaxation time measurements of human lymph nodes in adults with and without lymphatic insufficiency: Implications for magnetic resonance lymphatic imaging.
Crescenzi R; Donahue PM; Braxton VG; Scott AO; Mahany HB; Lants SK; Donahue MJ
NMR Biomed; 2018 Dec; 31(12):e4009. PubMed ID: 30311705
[TBL] [Abstract] [Full Text] [Related]
9. Expression and Clinical Significance of Herpes Virus Entry Mediator (hvem) in breast cancer.
Tsang JYS; Chan KW; Ni YB; Hlaing T; Hu J; Chan SK; Cheung SY; Tse GM
Ann Surg Oncol; 2017 Dec; 24(13):4042-4050. PubMed ID: 28612127
[TBL] [Abstract] [Full Text] [Related]
10. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract] [Full Text] [Related]
11. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract] [Full Text] [Related]
12. LIGHT, a novel ligand for lymphotoxin beta receptor and tr2/hvem induces apoptosis and suppresses in vivo tumor formation via gene transfer.
Zhai Y; Guo R; Hsu TL; Yu GL; Ni J; Kwon BS; Jiang GW; Lu J; Tan J; Ugustus M; Carter K; Rojas L; Zhu F; Lincoln C; Endress G; Xing L; Wang S; Oh KO; Gentz R; Ruben S; Lippman ME; Hsieh SL; Yang D
J Clin Invest; 1998 Sep; 102(6):1142-51. PubMed ID: 9739048
[TBL] [Abstract] [Full Text] [Related]
